Health gains and financial risk protection afforded by public financing of selected interventions in Ethiopia: an extended cost-effectiveness analysis

Publication date: May 2015 Source:The Lancet Global Health, Volume 3, Issue 5 Author(s): Stéphane Verguet , Zachary D Olson , Joseph B Babigumira , Dawit Desalegn , Kjell Arne Johansson , Margaret E Kruk , Carol E Levin , Rachel A Nugent , Clint Pecenka , Mark G Shrime , Solomon Tessema Memirie , David A Watkins , Dean T Jamison Background The way in which a government chooses to finance a health intervention can affect the uptake of health interventions and consequently the extent of health gains. In addition to health gains, some policies such as public finance can insure against catastrophic health expenditures. We aimed to evaluate the health and financial risk protection benefits of selected interventions that could be publicly financed by the government of Ethiopia. Methods We used extended cost-effectiveness analysis to assess the health gains (deaths averted) and financial risk protection afforded (cases of poverty averted) by a bundle of nine (among many other) interventions that the Government of Ethiopia aims to make universally available. These nine interventions were measles vaccination, rotavirus vaccination, pneumococcal conjugate vaccination, diarrhoea treatment, malaria treatment, pneumonia treatment, caesarean section surgery, hypertension treatment, and tuberculosis treatment. Findings Our analysis shows that, per dollar spent by the Ethiopian Government, the interventions that avert the most deaths are measles vaccination (367 deaths ...
Source: The Lancet Global Health - Category: Global & Universal Source Type: research